• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TUCATINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • TUCATINIB chembl:CHEMBL3989868 Antineoplastic

    Alternate Names:

    ONT-380
    ARRY-380
    TUCATINIB

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Moulder et al., 2017, Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC)., Clin. Cancer Res.
    Kulukian A et al., 2020, Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models., Mol Cancer Ther
    Borges VF et al., 2018, Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial., JAMA Oncol
  • TUCATINIB   ERBB2

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type stomach carcinoma
    Approval Status Phase I
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    28053022 32241871 29955792


    Sources:
    TALC TdgClinicalTrial JAX-CKB TTD

  • TdgClinicalTrial: ARRY-380

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Tucatinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Moulder et al., 2017, Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC)., Clin. Cancer Res.

  • TTD: ARRY-380

    • Version: 2020.06.01

    Alternate Names:
    D0M8AI TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Tucatinib

    • Version: 2020.06.01

    Alternate Names:
    D09GRX TTD Drug ID

    Drug Info:

    Publications:

  • TALC: ARRY-380

    • Version: 12-May-2016

    Alternate Names:
    ARRY-380 Primary Drug Name
    ARRY-380 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3989868

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • JAX-CKB: ARRY-380

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21